PARSIPPANY, N.J., Jan. 21, 2020 /PRNewswire/ -- Onkos Surgical, Inc. a leader in the field of musculoskeletal oncology and personalized orthopaedics announced today a multi-year agreement with Integrum AB (INTEG B: Nasdaq First North exchange). The collaboration between companies will commence immediately and will be focused on expanding the US market for Integrum's OPRA™ (Osseoanchored Prostheses for the Rehabilitation of Amputees) Implant System; a revolutionary osseoinstegrated bone-anchored prosthetic technology.
Patrick Treacy, co-founder and CEO stated, "We are delighted to partner with Dr. Brånemark and Integrum, global experts and leading pioneers in the field of osseointegration. Integrum continues to revolutionize the field of bone anchored prosthetics and, given our focus in limb salvage, the OPRA™ technology is complementary to our portfolio strategy. The combined expertise of both companies will provide surgeons with greater access to advanced bone anchored prosthetics and provide patients with meaningful reconstructive options."
The OPRA™ Implant System is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur and after a healing time of several months the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.
"We are pleased to partner with a world-class company like Onkos Surgical for the benefit of the US market. I'm convinced that together Integrum and Onkos can accelerate adoption of the OPRA™ technology, providing more options for amputees wanting to take advantage of this remarkable technology," remarked Maria Lopez, Integrum's CEO.
Cautions Concerning Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "future," "believes," "expects," "may," "will," "should," "potential," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, delays potentially caused by the need for institutional review board approval and product training, distribution challenges, unexpected product efficacy and safety concerns, product or raw material availability and other supply constraints. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law.
About Onkos Surgical
Based in Parsippany, N.J., Onkos Surgical is a privately held surgical oncology company founded in 2015. We believe that individuals with cancer requiring surgery deserve solutions designed specifically for them. This principle is the driving force behind our Precision Oncology initiatives. Built on a digital platform, our solutions are rooted in unmatched expertise in patient imaging analysis, personalized surgical planning, and the latest advancements in 3D printing. At Onkos, we are passionate about reducing complexity for our customers and addressing the clinical challenges associated with tumor surgery. www.onkossurgical.com
About Integrum
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations towards an improved quality of life. A thorough surgical experience gained over two decades has led to development of Integrum's system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum is the worldwide scientific and thought leader in this area treating hundreds of patients from all parts of the world including clinical centers in the US. Integrum's OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA-approved technology for bone-anchored prosthetics available in the US. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.
Onkos Surgical Contact
Sean P. Curry, SVP Commercial Operations
scurry@onkossurgical.com
(973) 264-5400
Integrum Contact
Maria Lopez, CEO
maria.lopez@integrum.se
+46 708 46 10 69
View original content to download multimedia:http://www.prnewswire.com/news-releases/onkos-surgical-partners-with-integrum-to-expand-us-market-for-the-opra-implant-system-a-revolutionary-osseointegration-and-bone-anchored-prosthetic-technology-300990009.html
SOURCE Onkos Surgical
